Clinical Trial: A Study to Evaluate the Safety and Pharmacokinetics of RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07558915) titled 'A Study to Evaluate the Safety and Pharmacokinetics of RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)' on April 24.

Brief Summary: This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators [IMiDs], and anti-cluster of differentiation 38 [anti-CD38] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

Study Start Date: May 01

Study Type: INTERVENTIONA...